<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Cir Cardiovasc</journal-id><journal-title-group><journal-title>Revista Brasileira de Cirurgia Cardiovascular : &#x000f3;rg&#x000e3;o oficial da Sociedade Brasileira de Cirurgia Cardiovascular</journal-title></journal-title-group><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24598948</article-id><article-id pub-id-type="pmc">4389427</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20130074</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Myocardial protection with prophylactic oral metoprolol during coronary
artery bypass grafting surgery: evaluation by troponin I</article-title><trans-title-group xml:lang="pt"><trans-title>Prote&#x000e7;&#x000e3;o card&#x000ed;aca com uso profil&#x000e1;tico de betabloqueador oral em cirurgia
de revasculariza&#x000e7;&#x000e3;o mioc&#x000e1;rdica: avalia&#x000e7;&#x000e3;o pela troponina I</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rossi Neto</surname><given-names>Jo&#x000e3;o Manoel</given-names></name><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Gun</surname><given-names>Carlos</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Rui Fernando</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>de Almeida</surname><given-names>Antonio Flavio Sanchez</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Issa</surname><given-names>Mario</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Amato</surname><given-names>Vivian Lener</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Dinkhuysen</surname><given-names>Jarbas J.</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Piegas</surname><given-names>Leopoldo Soares</given-names></name><degrees>MD, PhD</degrees></contrib><aff> Instituto Dante Pazzanese de Cardiologia (IDPC), S&#x000e3;o Paulo, SP, Brazil.</aff></contrib-group><author-notes><corresp id="c01">Correspondence address: Jo&#x000e3;o Manoel Rossi Neto, Instituto Dante
Pazzanese de Cardiologia, Ambulat&#x000f3;rio novo-Setor de Disfun&#x000e7;&#x000e3;o Ventricular, Av. Dante
Pazzanese, 500 - Vila Mariana - S&#x000e3;o Paulo, SP, Brazil - Zip code: 04012-180. E-mail:
<email>jmrossi@sti.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2013</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2013</year></pub-date><volume>28</volume><issue>4</issue><fpage>449</fpage><lpage>454</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2013</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Biochemical markers of myocardial injury are frequently altered after cardiac
surgery. So far there is no evidence whether oral beta-blockers may reduce
myocardial injury after coronary artery bypass grafting. </p></sec><sec><title>Objective</title><p>To determine if oral administration of prophylactic metoprolol reduces the release
of cardiac troponin I in isolated coronary artery bypass grafting, not complicated
by new Q waves. </p></sec><sec><title>Methods</title><p>A prospective randomized study, including 68 patients, divided in 2 groups: Group
A (n=33, control) and B (n=35, beta-blockers). In group B, metoprolol tartrate was
administered 200 mg/day. The myocardial injury was assessed by troponin I with 1
hour and 12 hours after coronary artery bypass grafting. </p></sec><sec><title>Results</title><p>No significant difference between groups regarding pre-surgical, surgical,
complication in intensive care (15% <italic>versus</italic> 14%,
<italic>P</italic>=0.92) and the total number of hospital events (21%
<italic>versus</italic> 14%, <italic>P</italic>=0.45) was observed. The median
value of troponin I with 12 hours in the study population was 3.3 ng/ml and was
lower in group B than in group A (2.5 ng/ml <italic>versus</italic> 3.7 ng/ml,
<italic>P</italic>&#x0003c;0,05). In the multivariate analysis, the variables that
have shown to be independent predictors of troponin I release after 12 hours were:
no beta-blockers administration and number of vessels treated. </p></sec><sec><title>Conclusion</title><p>The results of this study in uncomplicated coronary artery bypass grafting,
comparing the postoperative release of troponin I at 12 hours between the control
group and who used oral prophylactic metoprolol for at least 72 hours, allow to
conclude that there was less myocardial injury in the betablocker group, giving
some degree of myocardial protection.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Introdu&#x000e7;&#x000e3;o</title><p>Os marcadores bioqu&#x000ed;micos de les&#x000e3;o mioc&#x000e1;rdica est&#x000e3;o frequentemente alterados ap&#x000f3;s
cirurgia card&#x000ed;aca. At&#x000e9; o momento n&#x000e3;o existem evid&#x000ea;ncias de que o betabloqueador
oral possa reduzir a les&#x000e3;o mioc&#x000e1;rdica ap&#x000f3;s cirurgia de revasculariza&#x000e7;&#x000e3;o
mioc&#x000e1;rdica. </p></sec><sec><title>Objetivo </title><p>Determinar se a administra&#x000e7;&#x000e3;o oral profil&#x000e1;tica de metoprolol reduz a libera&#x000e7;&#x000e3;o de
troponina card&#x000ed;aca I na cirurgia de revasculariza&#x000e7;&#x000e3;o mioc&#x000e1;rdica isolada n&#x000e3;o
complicada por novas ondas Q. </p></sec><sec><title>M&#x000e9;todos</title><p>Estudo prospectivo, randomizado, incluindo 68 pacientes divididos em 2 grupos:
Grupo A (n=33, controle) e B (n=35, betabloqueador). No grupo B, o tartarato de
metoprolol foi administrado na dose de 200 mg/dia. A les&#x000e3;o mioc&#x000e1;rdica foi avaliada
pela troponina I com 1 hora e 12 horas ap&#x000f3;s a cirurgia de revasculariza&#x000e7;&#x000e3;o
mioc&#x000e1;rdica. </p></sec><sec><title>Resultados</title><p>N&#x000e3;o foi observada diferen&#x000e7;a significativa entre os grupos quanto &#x000e0;s vari&#x000e1;veis
pr&#x000e9;-cir&#x000fa;rgicas, cir&#x000fa;rgicas, incid&#x000ea;ncia de complica&#x000e7;&#x000f5;es na terapia intensiva (15%
<italic>versus</italic> 14%; <italic>P</italic>=0,92) e o n&#x000fa;mero total de
eventos hospitalares (21% <italic>versus</italic> 14%; <italic>P</italic>=0,45). O
valor da mediana da troponina I com 12 horas na popula&#x000e7;&#x000e3;o estudada foi de 3,3
ng/ml e foi menor no grupo B do que no grupo A (2,5 ng/ml <italic>versus</italic>
3,7 ng/ml; <italic>P</italic>&#x0003c;0,05). Na an&#x000e1;lise multivariada, as vari&#x000e1;veis que
demonstraram serem preditoras independentes da libera&#x000e7;&#x000e3;o de troponina card&#x000ed;aca I
com 12 horas foram: n&#x000e3;o uso de betabloqueadores e n&#x000fa;mero de vasos tratados. </p></sec><sec><title>Conclus&#x000e3;o</title><p>Os resultados desta investiga&#x000e7;&#x000e3;o na cirurgia de revasculariza&#x000e7;&#x000e3;o mioc&#x000e1;rdica
isolada, n&#x000e3;o complicada, comparando a libera&#x000e7;&#x000e3;o p&#x000f3;s-operat&#x000f3;ria de troponina
card&#x000ed;aca I com 12 horas entre os grupos controle e o que usou metoprolol oral
profil&#x000e1;tico por pelo menos 72 horas, permitem concluir que houve menor les&#x000e3;o
mioc&#x000e1;rdica no grupo betabloqueador, conferindo algum grau de prote&#x000e7;&#x000e3;o
mioc&#x000e1;rdica.</p></sec></trans-abstract><kwd-group><kwd>Troponin I</kwd><kwd>Postoperative care</kwd><kwd>Adrenergic beta-antagonists</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>An increase in troponin levels is observed following cardiac surgery, indicating
myocardial injury <sup>[<xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>]</sup>. The values considered normal or expected after coronary
artery bypass grafting (CABG) suffer multifactorial influences such as type of surgery,
duration of ischemia and myocardial protection, inflammatory response, reperfusion
injury, excessive stretching and contraction of the heart, atheromatous embolism,
inadequate coronary perfusion and excessive perioperative cardiac work.</p><p>Beta-blockers can be defined as pharmacologic agents that antagonize specifically,
competitive and reversible the action of endogenous or exogenous catecholamine in
beta-adrenergic receptors. Particularly in the heart, beta-adrenergic stimulation leads
to increased heart rate and myocardial contractility. Depending upon the selective
ability to antagonize the effects of catecholamines in certain tissues at doses lower
than those required in others, beta-blockers may be classified as selective and
non-selective. The beta-1 selective blockers are considered cardioselective because the
heart contains predominantly beta-1 and less beta-2; since the bronchodilation is
mediated by beta-2 receptors, and this characteristic is dose-dependent and decreases or
disappears when employing high doses. Possible deleterious effects resulting from the
use of beta-blockers that could cause myocardial depression and/or worsening of existing
lung disease, however, are of concern for some cardiac surgeons.</p><p>The clinical benefits of beta-blocker therapy have been proven in the treatment of
myocardial infarction, heart failure, protection of preoperative patients with ischemic
heart disease and in the prevention of atrial fibrillation postoperatively <sup>[<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>]</sup>.</p><p>From the clinical and research perspective, it is desirable to describe the plasma
levels of markers of myocardial necrosis (MMN) as troponins, released in CABG that are
not caused by infarction postoperatively and evaluate possible myocardial protection
procedures that could reduce the MI. It is plausible to expect that the results of the
protective effects of beta-blockers can be extrapolated to CABG. Therefore, the aim of
this study is to test the hypothesis that the prophylactic use of oral metoprolol
tartrate reduces MI, assessed by the release of troponin I (TnI) in the first 12 hours
of post-CABG alone and not complicated by the presence of new Q waves on the
electrocardiogram (EKG), conferring myocardial protection.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a randomized, open-label and single center study. Inclusion criteria for the
study were indication for CABG regardless of age or gender with signed informed consent
term. Exclusion criteria for the study were: previous use of beta-blockers;
contraindication to beta-blockers; clinical signs of systolic heart failure, global
ejection fraction less than 50%; CABG associated with other procedures (valve
replacement or aneurysmectomy or endoaneurysmorrhaphy), presence of new Q waves on EKG
during the period of stay in the Intensive Care Unit (ICU) and presence of acute
myocardial infarction less than 30 days of evolution.</p><p>All patients underwent CABG with the same surgical technique (intermittent aortic
clamping) and a graft of the left internal thoracic artery had to be implanted.</p><p>The metoprolol tartrate (oral) was initiated at least 72 hours before surgery, in the
target dose of 200 mg/day.</p><p>TnI concentrations were determined by immunometric method using the Immulite Analyser
(DPC - Diagnostic Products Corporation - Los Angeles, USA). Three samples of blood were
collected for the determination of TnI: in the preoperative period, with one hour and 12
hour arrival in the ICU. A program developed by the authors of the EuroSCORE was used
for the score calculation of each patient <sup>[<xref rid="r05" ref-type="bibr">5</xref>]</sup>.</p><p>The intercurrences and complications (inotropes &#x0003e;24 hours, intubation &#x0003e;24 hours,
temporary pacemaker, the ICU stay for &#x0003e;24 hours, stroke, atrial fibrillation, and
death) were registered in the medical record and transferred to the clinical form of the
study.</p><p>Due to the difficulty of finding information on the variability of the difference
between TnI between the two groups (with and without beta-blockers) initially several
simulations were performed to estimate the sample size. After the completion of the
study, the statistical difference (1.2) and standard deviation of the difference (1.7)
were calculated, and it was observed a test power of 85%.</p><p>Results were expressed as mean and standard error or median and quartiles for
quantitative variables, while qualitative variables were expressed as relative
frequencies. Possible associations between qualitative variables were evaluated using
the chi-square or Fisher exact test. For comparison of quantitative variables between
the control and beta-blocker groups was used t-test for variables with normal
distribution and for those without normal distribution (with an hour I TnI, TnI 12 hours
and number of vessels treated) the Mann-Whitney test was applied. The Spearman
correlation was used to examine the association between quantitative variables and Tn I
of 12 hours.</p><p>For the choice of the independent variables on the model of multivariate analysis,
variables that had significant correlation were selected and by clinical judgment the
ones that could also influence the release of TnI 12 hours. For the selection of best
model, which had a reduced number of variables the Akaike method was applied, that uses
a generalized linear model of gamma distribution (link function log). The gamma model
was selected by presenting a better fit in the residual analysis.</p><p>Results were considered statistically significant when <italic>P</italic>-values were
less than 0.05.</p><p>This study was approved by the Ethics Research Committee of our Institution (protocol
number: 2089).</p></sec><sec sec-type="results"><title>RESULTS</title><p>Initially 70 patients were selected and after recruitment, two cases were not considered
from the analysis because they had new Q waves on EKG 12 hours after surgery.</p><p>Patients were allocated for two groups, 33 (48.5%) patients in the control group, and
the other 35 (51.5%) in the beta-blocker group. The dose in one patient was reduced to
100 mg/day due to asymptomatic heart rate less than 50 bpm.</p><p>The clinical and surgical characteristics of the groups are described in <xref ref-type="table" rid="t01">Tables 1</xref>, <xref ref-type="table" rid="t02">2</xref>
and <xref ref-type="table" rid="t03">3</xref>.</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Qualitative variables, comparison of the control and beta-blocker groups.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">Control</th><th rowspan="1" colspan="1">Beta-blocker</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">N (%)</th><th rowspan="1" colspan="1">N (%)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">11 (33)</td><td rowspan="1" colspan="1">11 (31)</td><td rowspan="1" colspan="1">0.867</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Indication</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Stable angina</td><td rowspan="1" colspan="1">23 (70)</td><td rowspan="1" colspan="1">27 (80)</td><td rowspan="1" colspan="1">0.312</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Unstable angina</td><td rowspan="1" colspan="1">04 (12)</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Anatomic</td><td rowspan="1" colspan="1">02 (06)</td><td rowspan="1" colspan="1">04 (11)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Silent schemia</td><td rowspan="1" colspan="1">04 (12)</td><td rowspan="1" colspan="1">02 (06)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Prior infarction</td><td rowspan="1" colspan="1">12 (36)</td><td rowspan="1" colspan="1">16 (46)</td><td rowspan="1" colspan="1">0.434</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Prior revascularization</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.299</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Transient schemic attack</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">02 (06)</td><td rowspan="1" colspan="1">0.163</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">11 (33)</td><td rowspan="1" colspan="1">12 (34)</td><td rowspan="1" colspan="1">0.934</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">25 (76)</td><td rowspan="1" colspan="1">25 (71)</td><td rowspan="1" colspan="1">0.686</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td rowspan="1" colspan="1">18 (54)</td><td rowspan="1" colspan="1">25 (71)</td><td rowspan="1" colspan="1">0.149</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Current smoking</td><td rowspan="1" colspan="1">08 (24)</td><td rowspan="1" colspan="1">05 (14)</td><td rowspan="1" colspan="1">0.554</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Family history of CoI</td><td rowspan="1" colspan="1">05 (15)</td><td rowspan="1" colspan="1">08 (23)</td><td rowspan="1" colspan="1">0.419</td></tr></tbody></table><table-wrap-foot><p>N= number of patients; CoI= coronary insufficiency</p></table-wrap-foot></table-wrap><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Quantitative variables, comparison of the control and beta-blocker groups.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Control</th><th rowspan="1" colspan="1">Beta-blocker</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">Mean SE</th><th rowspan="1" colspan="1">Mean SE</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">59.0 1.7</td><td rowspan="1" colspan="1">57.9 1.4</td><td rowspan="1" colspan="1">0.619</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Weight (Kg)</td><td rowspan="1" colspan="1">72.3 3.0</td><td rowspan="1" colspan="1">74.8 2.4</td><td rowspan="1" colspan="1">0.519</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Height (m)</td><td rowspan="1" colspan="1">1.63 1.0</td><td rowspan="1" colspan="1">1.65 1.0</td><td rowspan="1" colspan="1">0.330</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">BMI (Kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">26.7 0.8</td><td rowspan="1" colspan="1">27.1 0.8</td><td rowspan="1" colspan="1">0.740</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Risk index - EUROSCORE</td><td rowspan="1" colspan="1">02.1 0.3</td><td rowspan="1" colspan="1">02.0 0.3</td><td rowspan="1" colspan="1">0.757</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Ejection fraction</td><td rowspan="1" colspan="1">64.0 1.0</td><td rowspan="1" colspan="1">66.3 1.1</td><td rowspan="1" colspan="1">0.153</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Pre-operative heart rate</td><td rowspan="1" colspan="1">73.8 1.7</td><td rowspan="1" colspan="1">68.0 1.7</td><td rowspan="1" colspan="1">0.021</td></tr></tbody></table><table-wrap-foot><p>SE= standard error; BMI= body mass index</p></table-wrap-foot></table-wrap><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Surgical characteristics in the control and beta-blocker groups.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">Beta-blocker group</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Mean SE</th><th align="center" rowspan="1" colspan="1">Mean SE</th><th align="center" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Perfusion time (minutes)</td><td align="center" rowspan="1" colspan="1">86.8 5.2</td><td align="center" rowspan="1" colspan="1">84.1 5.1</td><td align="center" rowspan="1" colspan="1">0.705</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Cross clamp time (minutes)</td><td align="center" rowspan="1" colspan="1">60.3 3.0</td><td align="center" rowspan="1" colspan="1">57.0 3.6</td><td align="center" rowspan="1" colspan="1">0.477</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">ICU stay (hours)</td><td align="center" rowspan="1" colspan="1">45.4 1.4</td><td align="center" rowspan="1" colspan="1">54.3 6.2</td><td align="center" rowspan="1" colspan="1">0.181</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Number of grafts performed</td><td align="center" rowspan="1" colspan="1">3.0 (2.0-3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (2.0-3.0)</td><td align="center" rowspan="1" colspan="1">0.215</td></tr></tbody></table></table-wrap><p><xref ref-type="table" rid="t04">Table 4</xref> presents the results of the values of Tn
I with 1 hour and 12 hours of arrival in the ICU between the control and beta-blockers.
TnI values were lower in the beta-blocker group than in the control group.</p><table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><p>Analysis of troponin I results (ng/ml) in both groups.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">Troponin I</th><th rowspan="1" colspan="1">Control Group</th><th rowspan="1" colspan="1">Beta-blocker Group</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">Median (25%-75%)</th><th rowspan="1" colspan="1">Median (25%-75%)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Pre-operative</td><td rowspan="1" colspan="1">0.5 (0.5-0.5)</td><td rowspan="1" colspan="1">0.5 (0.5-0.5)</td><td rowspan="1" colspan="1">0.303</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">At 1 hour</td><td rowspan="1" colspan="1">2.7 (1.2-5.0)</td><td rowspan="1" colspan="1">2.1 (1.0-4.2)</td><td rowspan="1" colspan="1">0.360</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">At 12 hours</td><td rowspan="1" colspan="1">3.7 (2.2-9.9)</td><td rowspan="1" colspan="1">2.5 (1.9-4.9)</td><td rowspan="1" colspan="1">0.048</td></tr></tbody></table></table-wrap><p>However, this difference was only statistically significant in the 12 hours
postoperatively data (2.50 <italic>versus</italic> 3.70, <italic>P</italic>=0.048).</p><p>The changes of TnI were analyzed 12 hours post-operative and their association with some
clinical and surgical variables. In addition to the variable group, univariate analysis
showed that the factors to be correlated with the release of TnI 12 hours were perfusion
time, cross clamp time and the number of grafts performed (<xref ref-type="table" rid="t05">Table 5</xref>). Although statistically significant, this relationship was
considered weak by analyzing the values of correlation (R).</p><table-wrap id="t05" orientation="portrait" position="float"><label>Table 5</label><caption><p>Correlation between troponin I at 12 hours of postoperative and variables which
could influence its release.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">Variable</th><th rowspan="1" colspan="1">Correlation (R)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Weight</td><td rowspan="1" colspan="1">-0.10</td><td rowspan="1" colspan="1">0.379</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Height</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.886</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">BMI (body mass index)</td><td rowspan="1" colspan="1">-0.17</td><td rowspan="1" colspan="1">0.160</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.622</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Ejection fraction</td><td rowspan="1" colspan="1">-0.10</td><td rowspan="1" colspan="1">0.557</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Preoperative heart rate</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.466</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Perfusion time</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">0.016</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Cross clamp time</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">0.011</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Number of grafts performed</td><td rowspan="1" colspan="1">0.36</td><td rowspan="1" colspan="1">0.003</td></tr></tbody></table></table-wrap><p>There was no significant difference in relation to postoperative complications in the
ICU and in-hospital events between groups (21% in the control group
<italic>versus</italic> 14% in patients with beta-blocker, <italic>P</italic>=0.454)
(<xref ref-type="table" rid="t06">Table 6</xref>).</p><table-wrap id="t06" orientation="portrait" position="float"><label>Table 6</label><caption><p>Comparison of complications in the intensive care unit and hospital events between
the control and beta-blocker groups.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Control Group</th><th rowspan="1" colspan="1">Beta-blocker Group</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">n (%)</th><th rowspan="1" colspan="1">n (%)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Complications in the ICU</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Inotropic agents &#x0003e; 24 hours</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">03 (09)</td><td rowspan="1" colspan="1">0.085</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Temporary pacemaker</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.299</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Intubation &#x0003e; 48 hours</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">03 (09)</td><td rowspan="1" colspan="1">0.332</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- ICU &#x0003e; 48 hours</td><td rowspan="1" colspan="1">04 (12)</td><td rowspan="1" colspan="1">05 (14)</td><td rowspan="1" colspan="1">0.792</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Stroke</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0.966</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Atrial fibrillation</td><td rowspan="1" colspan="1">03 (09)</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0.275</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- ICU deaths</td><td rowspan="1" colspan="1">00</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0.328</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Total complications in the ICU</td><td rowspan="1" colspan="1">06 (18)</td><td rowspan="1" colspan="1">05 (14)</td><td rowspan="1" colspan="1">0.457</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Hospital events</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Hospital deaths</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">01 (03)</td><td rowspan="1" colspan="1">0.966</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">- Total hospital events</td><td rowspan="1" colspan="1">07 (21)</td><td rowspan="1" colspan="1">05 (14)</td><td rowspan="1" colspan="1">0.454</td></tr></tbody></table><table-wrap-foot><p>n= number of patients; ICU= Intensive Care Unit</p></table-wrap-foot></table-wrap><p>In the final model of the multivariate analysis, the variables that have shown to be
independent predictors of TnI release after 12 hours were: no beta-blockers
administration and number of grafts required. <xref ref-type="table" rid="t07">Table
7</xref> shows the percentage increase and the results expected. No beta-blockers
administration increases in 22% the expected value of troponin 12 hours and for each
graft required adds a 33% increase.</p><table-wrap id="t07" orientation="portrait" position="float"><label>Table 7</label><caption><p>Results of the multivariate analysis of troponin I release at 12 hours.</p></caption><table frame="hsides" rules="groups"><thead><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">Expected Percentage</th><th rowspan="1" colspan="1">CI 95%</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr align="center"><th align="left" rowspan="1" colspan="1">
</th><th rowspan="1" colspan="1">Increase</th><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr align="center"><td align="left" rowspan="1" colspan="1">Control group</td><td rowspan="1" colspan="1">1.22</td><td rowspan="1" colspan="1">1.02-1.46</td><td rowspan="1" colspan="1">0.027</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Number of grafts performed</td><td rowspan="1" colspan="1">1.33</td><td rowspan="1" colspan="1">1.01-1.77</td><td rowspan="1" colspan="1">0.046</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Hospital events</td><td rowspan="1" colspan="1">1.65</td><td rowspan="1" colspan="1">0.97-2.80</td><td rowspan="1" colspan="1">0.063</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Perfusion time</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">0.99-1.01</td><td rowspan="1" colspan="1">0.077</td></tr><tr align="center"><td align="left" rowspan="1" colspan="1">Postoperative complications</td><td rowspan="1" colspan="1">0.64</td><td rowspan="1" colspan="1">0.36-1.14</td><td rowspan="1" colspan="1">0.132</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The results of this study prospectively evaluated 68 patients undergoing isolated CABG
revealed for the first time in literature, a myocardial injury reduction in the group
using oral beta-blocker at a dose of 200 mg/day for at least 72 hours
preoperatively.</p><p>Some demographic characteristics in the general population of the study should be
highlighted as the presence of women in one third of patients, average age below 60
years, more than a third with previous myocardial infarction, diabetes mellitus with a
third, more than 70% with hypertension, more than 50% with dyslipidemia and all with
ventricular function regarded as good. This population was considered low risk (mean
EuroSCORE 2.0). Clinical characteristics were distributed equally in both groups, except
for preoperative heart rate, which was lower in the beta-blocker group (73.8
<italic>versus</italic> 68.2, <italic>P</italic>=0.035).</p><p>The myocardial injury is associated with cardiac surgery and can be caused by different
mechanisms, including: direct trauma by suturing and manipulation of the heart; regional
or global ischemia by inadequate cardiac protection, coronary dissection, microvascular
events related to reperfusion or failure to perform the grafts <sup>[<xref rid="r06" ref-type="bibr">6</xref>]</sup>. Moreover, no biological marker is able
to distinguish the injury caused by infarction that occurs in small quantities in
myocardial cells, which usually are associated with the procedure itself <sup>[<xref rid="r06" ref-type="bibr">6</xref>]</sup>. However, the higher the value for a
cardiac biochemical marker after the procedure, the greater the myocardial injury,
regardless of the mechanism of injury. Despite the difficulties in interpreting the
troponin level after a CABG, it is known that the higher this value, the worse the
prognosis <sup>[<xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref>]</sup>.</p><p>In this study, patients who used beta-blockers had a significant reduction in the levels
of cTnI (2.50 ng/ml <italic>versus</italic> 3.70 ng/ml, <italic>P</italic>=0.048), with
a trend in the reduction of hospital events, despite not achieving statistical
significance (14% <italic>versus</italic> 21%, <italic>P</italic>=0.454). It was also
shown that the longer the perfusion time, the anoxic time, and the number of grafts
required, the higher levels of TnI at 12 hours postoperatively. However, in multivariate
analysis, independent predictors of troponin release were the number of grafts required
and the fact of not using beta-blockers (control group).</p><p>The clinical significance of this minimum or expected TnI amount has not yet been
elucidated. In this study, despite the lower release in the beta-blocker group, there
was no significant difference in relation to in-hospital events, probably because the
study was not designed with this objective and the sample size was insufficient.</p><p>On the other hand, the main interest of this study was to observe the behavior changes
of TnI with a single prophylactic pharmacological intervention. Therefore, we excluded
those who had a specific diagnostic criteria for perioperative myocardial infarction
(presence of new Q waves on postoperative) known to elevate a lot the level of TnI. The
use of a simple method of myocardial protection, as the use of prophylactic oral
metoprolol, combined with new advances in surgical techniques and postoperative care,
can further reduce the minimum expected release of markers of myocardial necrosis and
thus possibly improve prognosis in CABG.</p><p>The mechanisms of myocardial protection of beta-blockers in CABG are not yet fully
understood. Animal experiments suggest that beta-blockade is cardioprotective during
reperfusion, either by reduction in infarct size, improvement of ventricular function,
reduction in apoptosis or decrease of myocardial edema <sup>[<xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. The possible
mechanisms involved in this protection include reducing the release of oxygen free
radicals and adhesion to endothelium nuclear polymorphs (major source of inflammatory
response) <sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. During cardiac surgery
with extracorporeal circulation there is a significant increase in the levels of
catecholamines, resulting in an acute desensitization of beta-adrenergic receptors
induced by these agonists. It is a cause of myocardial depression that occurs after
surgery <sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Probably the mechanisms
of myocardial protection with the use of metoprolol are related, in part, with
reductions of some ischemic process or metabolic changes that occur after surgery. There
are no data in the literature to confirm whether reduced levels of TnI are the result of
minor trauma straight from the heart with the use of beta-blockers, and what role of
this mechanism in myocardial injury and its clinical relevance.</p><p>Limitations of this study include being a single center, there is no standardization of
the available tests for troponin, using intermittent clamping as surgical technique (and
not be applied to other techniques) and cases of infarction without Q-wave in post-CABG
are not identified, since there is no definition for diagnosis in clinical studies. This
study used a low-risk population, and therefore with lower prevalence of hospital
events, which may have contributed to no statistical differences between the groups.
Finally, a larger sample of patients could extend the results obtained, but as the
hospital morbidity and mortality are considered low in low-risk patients undergoing CABG
surgery, multicenter clinical trials would be needed with a very large population to
assess reduction of infarction postoperatively and hospital events with the use of
prophylactic beta-blockers in addition to the impact of the minimum TnI changes in the
possible risk factors and prognosis. There is a need to clarify whether changes of TnI
in non-complicated patients with new Q waves on EKG have any clinical consequences after
discharge, because this study was limited to in hospital follow up.</p><p>The clinical implications of this study allow us to assure that there is some degree of
myocardial injury even in uncomplicated patients and it becomes mandatory, therefore to
define which the minimum reference value of cTnI is after CABG and correlate the values
with prognosis. The reduction of TnI in the beta-blocker group in this study may help to
understand the benefits of this medication, since it is known that the higher the levels
of troponin, the worse the prognosis of patients, regardless of the pathophysiological
mechanisms involved <sup>[<xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The results of this research in isolated CABG, not complicated by the presence of new Q
waves on EKG, comparing the release of TnI with 12 hours postoperative between the
control group and who used oral prophylactic metoprolol for at least 72 hours, allow us
to conclude that there was less myocardial injury in the beta-blocker group, conferring
myocardial protection.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="other"><p>Work carried out at Instituto Dante Pazzanese de Cardiologia (IDPC), S&#x000e3;o Paulo, SP,
Brazil.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>JCF</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name><name><surname>Godoy</surname><given-names>MF</given-names></name><name><surname>Purini</surname><given-names>J</given-names><suffix>Neto</suffix></name><name><surname>Paula</surname><given-names>A</given-names><suffix>Neto</suffix></name><name><surname>Ramin</surname><given-names>SL</given-names></name><etal>et al</etal></person-group><article-title>Early evaluation of cardiac troponin I in patients submitted to
myocardial revascularization</article-title><source>Rev Bras Cir Cardiovasc</source><year>1999</year><volume>14</volume><issue>3</issue><fpage>247</fpage><lpage>253</lpage></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Abdelmeguid</surname><given-names>AE</given-names></name><name><surname>Kuntz</surname><given-names>RE</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Davidson</surname><given-names>CJ</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name><etal>et al</etal></person-group><article-title>Myonecrosis after revascularization procedures</article-title><source>J Am Coll Cardiol</source><year>1998</year><volume>31</volume><issue>2</issue><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">9462562</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>HT</given-names></name></person-group><article-title>Beta blockers in hypertension and cardiovascular
disease</article-title><source>BMJ</source><year>2007</year><volume>334</volume><issue>7600</issue><fpage>946</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">17478848</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaw</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>AV</given-names></name><name><surname>Masood</surname><given-names>I</given-names></name><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Saliba</surname><given-names>W</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name></person-group><article-title>Short- and long-term mortality associated with new-onset atrial
fibrillation after coronary artery bypass grafting: a systematic review and
meta-analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><issue>5</issue><fpage>1305</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">21247589</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Goldstone</surname><given-names>AR</given-names></name><name><surname>Nashef</surname><given-names>SA</given-names></name></person-group><article-title>The logistic EuroSCORE</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>9</issue><fpage>881</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">12727160</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Simoons</surname><given-names>ML</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><etal>et al</etal></person-group><article-title>Third universal definition of myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>60</volume><issue>16</issue><fpage>1581</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">22958960</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurati Buse</surname><given-names>GA</given-names></name><name><surname>Koller</surname><given-names>MT</given-names></name><name><surname>Grapow</surname><given-names>M</given-names></name><name><surname>Bolliger</surname><given-names>D</given-names></name><name><surname>Seeberger</surname><given-names>M</given-names></name><name><surname>Filipovic</surname><given-names>M</given-names></name></person-group><article-title>The prognostic value of troponin release after adult cardiac surgery:
a meta-analysis</article-title><source>Eur J Cardiothorac Surg</source><year>2010</year><volume>37</volume><issue>2</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">19699102</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domanski</surname><given-names>MJ</given-names></name><name><surname>Mahaffey</surname><given-names>K</given-names></name><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Brener</surname><given-names>SJ</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Hillis</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Association of myocardial enzyme elevation and survival following
coronary artery bypass graft surgery</article-title><source>JAMA</source><year>2011</year><volume>305</volume><issue>6</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">21304084</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usta</surname><given-names>E</given-names></name><name><surname>Mustafi</surname><given-names>M</given-names></name><name><surname>Straub</surname><given-names>A</given-names></name><name><surname>Ziemer</surname><given-names>G</given-names></name></person-group><article-title>The nonselective beta-blocker carvedilol suppresses apoptosis in human
cardiac tissue: a pilot study</article-title><source>Heart Surg Forum</source><year>2010</year><volume>13</volume><issue>4</issue><fpage>E218</fpage><lpage>E222</lpage><pub-id pub-id-type="pmid">20719722</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fannelop</surname><given-names>T</given-names></name><name><surname>Dahle</surname><given-names>GO</given-names></name><name><surname>Matre</surname><given-names>K</given-names></name><name><surname>Moen</surname><given-names>CA</given-names></name><name><surname>Mongstad</surname><given-names>A</given-names></name><name><surname>Eliassen</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Esmolol before 80 min of cardiac arrest with oxygenated cold blood
cardioplegia alleviates systolic dysfunction. An experimental study in
pigs</article-title><source>Eur J Cardiothorac Surg</source><year>2008</year><volume>33</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">18032058</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissler</surname><given-names>HJ</given-names></name></person-group><article-title>Reduction of myocardial reperfusion injury by high-dose beta-blockade
with esmolol</article-title><source>Thorac Cardiovasc Surg</source><year>2002</year><volume>50</volume><issue>6</issue><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">12457318</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>JV</given-names></name><name><surname>Landolfo</surname><given-names>KP</given-names></name><name><surname>Chesnut</surname><given-names>LC</given-names></name><name><surname>Bennett-Guerrero</surname><given-names>E</given-names></name><name><surname>Gerhardt</surname><given-names>MA</given-names></name><name><surname>Atwell</surname><given-names>DM</given-names></name><etal>et al</etal></person-group><article-title>Acute depression of myocardial beta-adrenergic receptor signaling
during cardiopulmonary bypass: impairment of the adenylyl cyclase
moiety</article-title><collab>Duke Heart Center Perioperative Desensitization Group</collab><source>Anesthesiology</source><year>1998</year><volume>89</volume><issue>3</issue><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">9743395</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>FP</given-names></name><name><surname>Pego-Fernandes</surname><given-names>PM</given-names></name><name><surname>Jatene</surname><given-names>FB</given-names></name><name><surname>Kwasnicka</surname><given-names>KL</given-names></name><name><surname>Strumz</surname><given-names>CMC</given-names></name><name><surname>Oliveira</surname><given-names>SA</given-names></name></person-group><article-title xml:lang="pt">Implica&#x000e7;&#x000e3;o progn&#x000f3;stica da creatino-quinase mioc&#x000e1;rdica e
troponina na revasculariza&#x000e7;&#x000e3;o do mioc&#x000e1;rdio</article-title><source>Rev Bras Cir Cardiovasc</source><year>2003</year><volume>18</volume><issue>3</issue><fpage>210</fpage><lpage>216</lpage></element-citation></ref></ref-list></back><floats-group><table-wrap orientation="portrait" id="d35e1716" position="float"><table frame="box" rules="groups"><thead><tr align="left"><th colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr align="left"><td rowspan="1" colspan="1">CABG</td><td rowspan="1" colspan="1">Coronary artery bypass grafting</td></tr><tr align="left"><td rowspan="1" colspan="1">EKG</td><td rowspan="1" colspan="1">Electrocardiogram</td></tr><tr align="left"><td rowspan="1" colspan="1">ICU</td><td rowspan="1" colspan="1">Intensive Care Unit</td></tr><tr align="left"><td rowspan="1" colspan="1">MMN</td><td rowspan="1" colspan="1">Markers of myocardial necrosis</td></tr><tr align="left"><td rowspan="1" colspan="1">TnI</td><td rowspan="1" colspan="1">Troponin I</td></tr></tbody></table></table-wrap><table-wrap orientation="portrait" id="d35e1748" position="float"><table frame="box" rules="groups"><thead><tr align="left"><th colspan="2" rowspan="1">Author's roles &#x00026; responsibilities</th></tr></thead><tbody><tr align="left"><td rowspan="1" colspan="1">JMRN</td><td rowspan="1" colspan="1">Protocol design, data collection, discussion of results and manuscript
writing</td></tr><tr align="left"><td rowspan="1" colspan="1">CG</td><td rowspan="1" colspan="1">Discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">RFR</td><td rowspan="1" colspan="1">Discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">AFSA</td><td rowspan="1" colspan="1">Surgical procedures and discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">MI</td><td rowspan="1" colspan="1">Surgical procedures and discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">VLA</td><td rowspan="1" colspan="1">Data collection and discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">JJD</td><td rowspan="1" colspan="1">Discussion of results</td></tr><tr align="left"><td rowspan="1" colspan="1">LSP</td><td rowspan="1" colspan="1">Protocol design, discussion of results and manuscript writing</td></tr></tbody></table></table-wrap></floats-group></article>